Recruiting nowNot phased
What this trial is trying to do
The researchers are testing whether electrochemotherapy—brief electrical pulses that help the chemotherapy drug bleomycin enter tumour cells—can shrink unresectable tumours inside organs. Treatment may be delivered through the skin or during keyhole or open surgery, depending on the lesion.
The idea is to offer local treatment when surgery cannot remove the tumour, including lesions near major blood vessels or nerves. The trial will measure objective response, meaning how many treated lesions shrink or disappear, rather than whether patients live longer or go longer before the cancer grows.
Worth knowing: This is a small, single-centre, single-arm investigation with no comparison group, and it includes visceral tumours of any histological type rather than colorectal cancer alone.
Written from the trial's own registry entry to explain what the researchers are testing and why. Nothing here is a result — this trial has not reported one — and it is not a view on whether the treatment works or on whether it would suit you.
| Registry number | NCT06753136 |
|---|---|
| Recruitment | Recruiting now |
| Phase | Not phased |
| Design | open label |
| Taking part | 24 people (planned) |
| Who can join | aged 18 Years to 99 Years |
| Run by | Istituto Oncologico Veneto IRCCS |
| Started | |
| Main results expected | |
| Record last updated |
What is being tested
- Device percutaneous, laparoscopic or laparotomy lesion electrochemotherapy
What it is measuring
Primary objective and endpoint
This is the trial's main question — the one it is designed and sized to answer. Anything else it reports is a secondary finding, and secondary findings are far more likely to be chance.
Not phased. Not a drug-phase trial. Often a device, a procedure, or a change in how care is delivered.
How the researchers describe it
This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneous metastases of different tumor histotypes.
Although still limited, the various experiences in the treatment of visceral localizations, particularly in liver metastases from colorectal cancer are promising and show that electrochemotherapy is a safe treatment, even in the case of lesions near large vessels or nerves. The investigators therefore propose a clinical investigation with a Medical Device according to EU Regulation 745/2017, using electrochemotherapy (Cliniporator) with bleomycin for the treatment of visceral, primary or secondary, unresectable localizations, with percutaneous or intraoperative technique (laparoscopic or laparotomy), as needed.
Written by the trial’s sponsor, quoted from its ClinicalTrials.gov record.
What this trial is looking for
- Any genotype
- Colon
Read automatically from the criteria below, to make the list searchable. It is a summary of what the text mentions, not a decision about whether you qualify — and where the two disagree, the criteria are right and this is wrong.
Who the trial is looking for
Inclusion Criteria
- Male/Female ≥ 18 years
- Ability to understand the proposed treatment and express an informed acceptance by signing the informed consent
- Diagnosis of primary and/or secondary visceral localizations of any histotype
- Patients who are not eligible for standard curative procedures
Exclusion Criteria
- Absolute contraindications to invasive procedures
- Concomitant presence of brain, lung, bone metastases
- Uncorrectable coagulation changes
- Bleomycin allergy
- Absolute contraindications to taking Bleomycin
- Poor respiratory function or pulmonary fibrosis
- Acute lung infections
- Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study
This is an extract. Whether you qualify is decided by the trial team against the full criteria, not by reading this page. Read the full eligibility criteria
Where it is running
Running at 1 site. Listed in: Italy.
Individual hospitals, and whether each is currently open, are listed on the registry record. Sites open and close throughout a trial.
Worth asking your oncology team
Being listed here is not a recommendation, and no one page can tell you whether a trial is right for you. These are the questions it raises.
- Is this trial open at a hospital I could realistically travel to?
- Given my stage, my previous treatment and my tumour's molecular profile, would I be eligible?
- What would I be giving up by joining — is the comparison arm the treatment I would otherwise be having?
- What is already known about the safety of what is being tested?
The source
Registry record NCT06753136, registered by Istituto Oncologico Veneto IRCCS on ClinicalTrials.gov, a public database run by the US National Library of Medicine. The details on this page come from that record and are only ever as current as the sponsor has kept it.
This is a listing of a registered clinical trial, reproduced for information. It is not a recommendation, this site has no connection to the trial or its sponsor, and being listed here says nothing about whether the treatment works. Talk to your own oncology team before pursuing any trial.
This article summarises published research for general information. It is not medical advice, and it is not a substitute for a conversation with your own oncology team, who know your case. Do not start, stop, or change any treatment or supplement on the basis of what you read here.